Latest News from Gb Sciences

Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

As seen on Worldwide Business with Kathy Ireland

Choose Your Area Of Interest


GBLX’s novel drug discovery program produced 6 issued US and 4 issued international patents, as well as 15 US and 49 international patent-pending applications. We have 5 preclinical phase drug programs in our pipeline, and our Parkinson’s therapeutics are being prepared for a First-in-Man trial.

Research Partners

The strength of our R & D pipeline has been the participation of world class researchers from 9 international universities over the past 7 years. Together, we have assembled the ultimate toolkit to create the future of medicine; AI technology, plant-based medicine, and hard sciences.

Development Partners

Translating new drug principles into real world medicines requires expertise in several disciplines. Our partners help make our dream of novel plant-inspired medicines a reality by providing expertise in cGMP-certified active ingredients and novel oral delivery methods.


Our Goal is to preserve the efficacy of plant-based medicines while reducing their complexity for standardization.

Our Strategy is to combine our proprietary PhAROS Drug Discovery Platform and High Throughput Screening of Cell and Animal Models of Specific Disease Processes to Create Rationally-Designed, Minimum Essential Mixtures.

Here are the latest articles by Gb Sciences.

Navigating the COVID-19 Pandemic: A Novel Cannabinoid-Based Treatment Strategy

Pharma’s Almanac: Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures

University of Lethbridge researching possible Parkinson’s disease treatments

Potential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells

Terpenes & Testing: Harnessing the Power of Cannabis-Derived Ingredients for the Prescription Drug Market

TechRepublic: Drug discovery company works with ethnobotanists and data scientists

Cannabis Business Times: ‘This is Going to Change the Way People Think About Medicine’: Q&A with Dr. Andrea Small-Howard

Medicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice

Pharma’s Almanac: Exploring the Natural Pharmacopeia and Incubating a Biotech Company  


Here are the latest podcasts by Gb Sciences.

Stock Day Media: Interview with Andrea Small-Howard of Gb Sciences

Cannabis Business Times: Beyond the Show with Dr. Andrea Small-Howard

Terpenes and Testing: The Podcast with Andrea Small-Howard PhD

DocWire Podcast: Dr. Andrea Small-Howard, Gb Sciences, Talks Plant-Based Therapies for Parkinson's Disease

IDC Podcast: Bringing Medicines to Market Faster Through Analytics & Machine Learning